allosteric mutant IDH1/2 dual inhibitor

oral, brain penetrant, completed Ph. I in HV

from SBDD of prior mIDH inhibitor

ACS Med. Chem. Lett., 2020, 11, 101-107

Agios Pharmaceuticals, Cambridge, MA

AG-881

AG-881 (vorasidenib) (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: